This HTML5 document contains 38 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n9http://linked.opendata.cz/resource/drugbank/drug/DB05444/identifier/pubchem-compound/
dctermshttp://purl.org/dc/terms/
n11http://linked.opendata.cz/resource/drugbank/drug/DB05444/identifier/drugbank/
n7http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n10http://linked.opendata.cz/resource/drugbank/drug/DB05444/identifier/chemspider/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB05444
rdf:type
n3:Drug
n3:description
BRX-235 (iroxanadine) is a a novel small molecule synthesized by Biorex, Hungary that acts as a cardioprotective agent. It induces phosphorylation of p38 SAPK, which plays an important role in EC homeostasis. endothelial cell (EC). EC function plays a central role in vascular diseases (e.g. atherosclerosis, restenosis, diabetic angiopathies, microvascular angina, peripheral arterial disease). BRX-235 also causes translocation of calcium-dependent protein kinase C isoform to membranes.
n3:generalReferences
# Kabakov AE, Budagova KR, Malyutina YV, Latchman DS, Csermely P: Pharmacological attenuation of apoptosis in reoxygenated endothelial cells. Cell Mol Life Sci. 2004 Dec;61(24):3076-86. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15583868 # Denes L, Jednakovits A, Hargitai J, Penzes Z, Balla A, Talosi L, Krajcsi P, Csermely P: Pharmacologically activated migration of aortic endothelial cells is mediated through p38 SAPK. Br J Pharmacol. 2002 Jun;136(4):597-603. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12055138
n3:group
investigational
n3:indication
Investigated for use/treatment in atherosclerosis and vascular diseases as a cardioprotective agent. Its use has also been suggested for the prevention of early restenosis following vascular surgery or balloon angioplasty.
owl:sameAs
n7:DB05444
dcterms:title
BRX-235
adms:identifier
n9:6421776 n10:4927305 n11:DB05444
n3:mechanismOfAction
BRX-235 induces phosphorylation of p38 SAPK, which plays an important role in EC (endothelial cell) homeostasis.
n3:synonym
iroxanadine
n3:IUPAC-Name
n4:271B43C4-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B43CA-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B43C9-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B43C6-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B43C7-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B43C8-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B43C2-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B43C0-363D-11E5-9242-09173F13E4C5 n4:271B43C3-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B43C1-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B43D0-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B43D1-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B43CB-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B43CC-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B43CE-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B43CD-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B43CF-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B43D6-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B43D8-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B43D9-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B43D5-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B43D4-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B43D7-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B43C5-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B43D2-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B43D3-363D-11E5-9242-09173F13E4C5